Malignant Pleural Effusion Clinical Trial
Official title:
A Phase Ib/II Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Patients With Malignant Pleural Effusion
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE. This is a Phase Ib/II clinical trial to evaluate the safety and tolerability of administering bevacizumab and camrelizumab into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
This study is a phase Ib/II, single arm study with main purpose to evaluate the safety, tolerability and efficacy of intrapleural administration of bevacizumab and camrelizumab in subjects with malignant pleural effusion. The study aims to recruit 9 - 15 subjects in phase 1, and once the safety, tolerability and the preliminary efficacy of bevacizumab and camrelizumab reach an optimal target exposure for recommended dose (RD), phase 2a will be opened for enrolment of approximately 40 subjects ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
| Recruiting |
NCT04793607 -
Interventions for Malignant Pleural Effusions Impact on Fatigue
|
||
| Recruiting |
NCT03987087 -
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
|
Phase 2 | |
| Recruiting |
NCT02942043 -
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01997190 -
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
|
Phase 1 | |
| Completed |
NCT00564733 -
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04131231 -
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
|
N/A | |
| Completed |
NCT02674243 -
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
|
Phase 3 | |
| Terminated |
NCT01004510 -
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT00313066 -
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
|
Phase 4 | |
| Terminated |
NCT04236037 -
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
|
N/A | |
| Completed |
NCT05372055 -
Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
|
||
| Not yet recruiting |
NCT04914598 -
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
|
Phase 3 | |
| Recruiting |
NCT04322136 -
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
|
N/A | |
| Recruiting |
NCT03973957 -
Talc Outpatient Pleurodesis With Indwelling Catheter
|
N/A | |
| Recruiting |
NCT05923515 -
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
|
Phase 1 | |
| Completed |
NCT02649894 -
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
|
N/A | |
| Recruiting |
NCT03403855 -
Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients
|
N/A |